Catalog No.S1152

PLX-4720 Chemical Structure

Molecular Weight(MW): 413.83

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

9 Customer Reviews

  • Combinatorial knockdown of NF1 and C-RAF abrogates NF1-mediated resistance to B-RAF inhibition at the level of ERK phosphorylation. A375 cells were infected with NF1 shRNA and treated with either DMSO or PLX4720 for 16 h. Cell lysates were analyzed for the indicated proteins.

    Cancer Discov 2013 3, 350-62. PLX-4720 purchased from Selleck.

    (D)Melanoma cell lines were treated with 0.5 uM Pi-103 and/or 2 uM PLX4720 for 4 h. Samples were analyzed by Western blotting for the indicated proteins. β-Actin served as a loading control. (E) Melanoma cell lines were treated with a dilution series of Pi-103 either alone or in combination with the BRAFV600E inhibitor PLX4720 at a concentration of 3 uM (D10) or 1 uM (453A0) for 3 d. Total cell numbers were determined with a cell titer blue assay. The Y-axis represents the percentage of living cells.

    Genes Dev 2012 26, 1055-69. PLX-4720 purchased from Selleck.

  • RAF inhibitors induce dimer formation between KSR and RAF, and activate KSR by CRAF. (A) GDC0879 but not PLX4720 induces BRAF/CRAF dimers. Cells overexpressing myc-CRAF and BRAF were treated with drug for 1 h and CRAF immunoprecipitates were immunoblotted for BRAF and CRAF (epitope tagged with myc). (B) GDC0879 but not PLX4720 enhances KSR/BRAF complexes. KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and BRAF after treatment with the indicated drug for 1 h and immunoblotted using antibodies to BRAF. (C) Both GDC0879 and PLX4720 induce KSR/CRAF complexes.KSR immunoprecipitates were prepared from cells overexpressing FLAG-KSR and myc-CRAF after treatment with the indicated drug for 1 h and immunoblotted for CRAF using myc antibodies. (D and E) Requirement of KSR for drug-induced ERK activation. Lysates fromwild-type and KSR deficient fibroblasts, transfected with RASV12, were treated with the indicated doses of either GDC-0879 (D) or PLX4720 (E) for 1 h. Lysates were immunoblotted for phospho-ERK1 and 2, ERK2, and RASV12. (F) KSR and CRAF cooperate to activate MEK. Cells expressing the indicated constructs were treated with a 50 μM PLX4720 for 2 h before cell lysates were prepared and analyzed for pMEK by immunoblotting. CRAF(TM) refers to the T421M gatekeeper mutant that cannot bind to the drug(4). (G) KSR in vitro kinase reactions. Cells were cotransfected with WT or ATP binding deficient KSR and CRAF and immunoprecipitates prepared after cells were treated with an activating dose of PLX (10 μM) for 1 h. KSR immunoprecipitates were prepared, pretreated with 50 uM PLX4720 to inhibit coprecipitating RAF activity, and then tested for kinase activity using purified MEK. MEK phosphorylation was detected using a pMEK specific antibody.

    Proc Natl Acad Sci USA 2011 108, 6067-6072. PLX-4720 purchased from Selleck.

    PTEN predicts for PLX4720-induced apoptosis. A, basal PTEN and phospho-AKT(pAKT; S473, T308) expression in PTENt (WM164, 451Lu, SK-mel-28, WM983A, WM35, WM51) and PTEN (WM239A, WM266-4, WM793, M233, WM9, 1205Lu) melanoma cell lines. B, MTT assay of PTENt (gray)-expressing versus PTEN (black) cell lines. C, PTENt cells are more sensitive than PTEN cells to PLX4720-mediated apoptosis. Cells treated for 48 hours with 3 or 10 μmol/L PLX4720 before being stained for TMRM and Annexin-V. Apoptosis was measured by flow cytometry. Data shows mean SE mean of 3 independent experiments.*, PTENt cohort significantly different from PTEN cohort(P < 0.05).

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

  • Loss of PTEN is associated with PI3K/AKT signaling following BRAF inhibition. A, PTENt (WM35, WM164, WM983A) and PTEN (M233, WM9,WM793, 1205Lu) cells were treated with PLX4720 (24 hours: 0.03-3 μmol/L) and probed for phospho-PDK1 (pPDK1), total PDK1, phospho-AKT (pAKT), total AKT (tAKT), phospho-S6 (pS6), and total S6. Numbers indicate relative intensity of pPDK1 normalized to PDK1 and pAKT normalized to tAKT. B, PLX4720 increases pAKT following PTEN knockdown. WM35 cells were incubated with nontargeting siRNA (NT) or 2 different PTEN-specific siRNA's (PTEN) before treatment with either vehicle or PLX4720 (3 μmol/L). C, siRNA knockdown of BRAF increases pAKT in melanoma cell lines that are PTEN. WM164 (PTENt) and WM793 (PTEN) cells were incubated with lipofectamine alone (L), nontargeting siRNA (NT), or BRAF-specific siRNA (BRAF). Protein was extracted, resolved, and probed for BRAF, pAKT, total AKT, and GAPDH.



    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

    Dual PI3K/BRAF inhibition upregulates BIM and enhances apoptosis in PTEN cells. A, left, Western blot of 1205Lu cells treated with PLX4720 (3 μmol/L, 48 hours), the PI3K inhibitor GDC-0941 (3 μmol/L, 48 hours), or both drugs in combination (PtG); right, immunofluorescence staining of BIM (green) and DAPI (blue) in PTEN cells following PLX4720 treatment (3 μmol/L, 48 hours), the PI3K inhibitor LY294002 (10 μmol/L, 48 hours), or both drugs in combination (PLXtLY). B, left, immunofluorescence staining of PTEN 1205Lu following combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48hours) increases nuclear localization of FOXO3a (green). DAPI is shown in blue. Magnification 40. Right, combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48 hours) increases PTEN WM793 BIM mRNA levels to those observed with single BRAF inhibition (3 μmol/L PLX4720, 48 hours) in the PTENt WM35. C, PTEN cells were treated with PLX4720 (3 μmol/L, 48 hours), GDC-0941 (3 μmol/L, 48hours), or a combination of the 2 drugs (3Pt3G) before Annexin-V staining was analyzed by flow cytometry (*, P < 0.05 between the drug combination and each inhibitor alone). D, combined BRAF/PI3K inhibitor treatment blocks the escape of 1205Lu cells (PTEN) from therapy. Spheroids of 1205Lu cells were treated with either PLX4720 alone (3 and 10 μmol/L: data shows 3 μmol/L), LY294002 (10 μmol/L) alone or a combination of the 2 drugs for 72 hours. In other studies, spheroids were treated with drugs for 72 hours and then allowed to recover for 120 hours. Micrograph shows viability staining (green ?live cells, red ?dead cells). Magnification 10.

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

  • LC-MRM identifies differential regulation of BIM in PTENt and PTEN cell lines following PLX4720 treatment. A, representative LC-MRM data showing the fold changes in the expression of Bak, Bax, Bcl-2, Bcl-w, Bcl-xL, BID, BIM, Bok, and Mcl-1 over internal standard in the WM164 (PTENt) and 1205Lu (PTEN) cell lines following treatment with PLX4720 (10 μmol/L, 0-48 hours). Statistical analysis of BIM fold change in PTEN versus PTENt. *, P < 0.05. B, Western blot showing BIM expression following PLX4720 treatment (10 μmol/L, 0-48 hours) in PTEN (WM793, 1205Lu) and WM164 cell lines (PTENt). C, immunofluorescence staining, showing expression of BIM and DAPI staining of PTEN (M233, WM9, WM793, 1205Lu) and PTENt (WM35, WM164, WM983A) cells following PLX4720 treatment (3 μmol/L, 48 hours).D, Western blot showing BAD phosphorylation following treatment with PLX4720 (0-48 hours) in PTEN (WM793,1205Lu) and PTENt WM164. Annexin V binding following treatment with 3 or 10 μmol/L PLX4720 (48 hours) showing increased apoptosis in WM793 stably overexpressing WT BAD. *, P < 0.05.

    Cancer Res 2011 71, 2750-2760. PLX-4720 purchased from Selleck.

    B-RafV600E mutated melanoma line, SK-MEL-28, was treated with different doses of PLX-4720 for 4 h or 22 h.  Cell lysates were analyzed by Western blotting to determine the levels of phosphorylated MEK1/2 (pMEK1/2) and phosphorylated ERK1/2 (pERK1/2). MEK1/2 is the substrate of B-Raf while ERK1/2 is the substrate of MEK1/2.  Data show that phosphorylation of MEK1/2 and ERK1/2 was significantly inhibited by PLX-4720 treatment although total MEK1/2 or ERK1/2 protein levels were not affected. No pMEK1/2 or pERK1/2 signal was detected even after prolonged exposure, indicating that the inhibitor at 1 μM is very effective in blocking the constitutive kinase activity of B-RafV600E.  This data is consistent with the previous result demonstrating the effect of PLX-4720 in the B-RafV600E mutated melanoma line, A375 – Fig. 2A, Nature 464:431 (2010)



    Dr. Jong-In Park of Medical College of Wisconsin. PLX-4720 purchased from Selleck.

  • A dose titration of PLX-4720 in A375 melanoma cells which possess a V600E B-Raf mutation.Effects of  increasing PLX-4720 dose on Erk phosphorylation and on tumor cell proliferation as determined by MTT  assay are shown.



    Dr. Daniel C.Cho of Harvard Medical School. PLX-4720 purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe0XotZUUN3ME2wMlA4PDV5IN88US=> NIr1U21USU6JRWK=
EoL-1-cell NGOy[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMUSxOlYh|ryP NVXsbZRjW0GQR1XS
M14 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD1yLkKxO|U4KM7:TR?= NGDSNFlUSU6JRWK=
CP50-MEL-B MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHvTWM2OD1yLkK5O|g1KM7:TR?= NV3mV3UzW0GQR1XS
A101D M33xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPLNHRKSzVyPUCuN|I2QDlizszN NWSwN3hiW0GQR1XS
G-361 NYHa[mh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jjUWlEPTB;MD6zOFY{PyEQvF2= MW\TRW5ITVJ?
HT-144 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXo[GlKSzVyPUCuN|Y{OjlizszN MorMV2FPT0WU
ACN MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTiTWM2OD1yLkO4OFc4KM7:TR?= M4PKfnNCVkeHUh?=
SH-4 NGPpbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHuTWM2OD1yLkSxOFIzKM7:TR?= MnqyV2FPT0WU
SK-MEL-3 M4naTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNUG1Olgh|ryP M1PJenNCVkeHUh?=
A375 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDsNpZKSzVyPUCuOlc{PTlizszN NYLFUnlwW0GQR1XS
MMAC-SF Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3wSYlKSzVyPUCuOlg3OTRizszN MnfhV2FPT0WU
BHT-101 NU[2WmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36yTWlEPTB;MD63NFcxOiEQvF2= MlPWV2FPT0WU
K5 M2rTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnHeYZmUUN3ME2wMlc3OTR6IN88US=> NUO4SoxqW0GQR1XS
BV-173 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfTTWM2OD1yLke5OlQ1KM7:TR?= NG\ne|JUSU6JRWK=
RVH-421 M4XkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfVXXZKSzVyPUCuPFY4QTZizszN M17iWHNCVkeHUh?=
HCC2218 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXQTWM2OD1yLki3PFQ1KM7:TR?= NWHMRW01W0GQR1XS
WM-115 NWfNN5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXEdo42UUN3ME2wMlg5Pjl{IN88US=> Ml7BV2FPT0WU
SK-MEL-28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwMES1Olkh|ryP NEL0d4tUSU6JRWK=
SK-MEL-30 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwM{OzPFYh|ryP MlL5V2FPT0WU
NCI-H209 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwNkC4OkDPxE1? M3jLcHNCVkeHUh?=
HTC-C3 NWS1bJlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjYTWM2OD1zLk[2Nlk1KM7:TR?= NWe0Z3BSW0GQR1XS
KARPAS-45 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmyU3VZUUN3ME2yMlA1QTd6IN88US=> MkHIV2FPT0WU
NCI-SNU-5 NIrIe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGeyOldKSzVyPUKuNVE6PjlizszN NIjxfJdUSU6JRWK=
KP-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrVTWM2OD1{LkOwO|g4KM7:TR?= NWL4dlB[W0GQR1XS
PA-1 NYnUU|hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TES2lEPTB;Mj63NlY4OyEQvF2= NUHIV3d3W0GQR1XS
HuO-3N1 NYHOToxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC1cmNKSzVyPUKuPFc6PDZizszN M2\WbnNCVkeHUh?=
NCI-H358 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\KeYFpUUN3ME2yMlkzOjN{IN88US=> NVzqSm9iW0GQR1XS
CTB-1 NIDZepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXruT2s3UUN3ME2zMlQxOTd4IN88US=> M3TtWHNCVkeHUh?=
697 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwNUWyOlYh|ryP MYfTRW5ITVJ?
CP66-MEL NWHzO5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRwMUW5Nlch|ryP Mmj4V2FPT0WU
NB13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrpRW1KSzVyPUSuOFkyPzlizszN MmryV2FPT0WU
DBTRG-05MG NGe1NnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLETWM2OD12LkWzN|I2KM7:TR?= NUfnfppSW0GQR1XS
A2058 MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPHTWM2OD12LkeyNVY1KM7:TR?= MmPYV2FPT0WU
8305C MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3ZeXlKSzVyPUWuNVg4OyEQvF2= M1\tV3NCVkeHUh?=
CHL-1 NFTJbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m4VGlEPTB;NT65O|YxOyEQvF2= NYq2e|loW0GQR1XS
TI-73 NFu1cnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPzSYdKSzVyPU[uNFA6ODJizszN M4PMd3NCVkeHUh?=
HT-1080 NFnvcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTZwMUC5OFYh|ryP NI\1OVhUSU6JRWK=
8-MG-BA NGTwdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3frWmlEPTB;Nj6xPFEzQSEQvF2= Mly2V2FPT0WU
NB7 M3zMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZwMkGzO|Mh|ryP M4LzRXNCVkeHUh?=
H4 NH\Ec4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K3bWlEPTB;Nj6yNlQ6OyEQvF2= MWfTRW5ITVJ?
CAL-72 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwNEW0NlMh|ryP NIq1RVBUSU6JRWK=
HCC1806 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTZwOEG5N|Eh|ryP NFrvcXpUSU6JRWK=
BCPAP M3\sWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwMkG3OlQh|ryP NWPHOFRQW0GQR1XS
LB2241-RCC MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfnTWM2OD15LkO2PVA4KM7:TR?= MWPTRW5ITVJ?
COLO-741 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRThwMEG2O|kh|ryP MoG3V2FPT0WU
SW982 NWfscJRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUToUFhvUUN3ME24MlQyPTF4IN88US=> M1HGO3NCVkeHUh?=
KY821 NVKxVZdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTlwMEWxO|gh|ryP MlS1V2FPT0WU
JVM-3 NH:5UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof2TWM2OD17LkW2PVk6KM7:TR?= NGHlSY1USU6JRWK=
RS4-11 NH:1RotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXPdXRKSzVyPUmuOlA1QCEQvF2= MV7TRW5ITVJ?
LXF-289 M1\KNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFyLkS1PEDPxE1? MUnTRW5ITVJ?
SK-MEL-24 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f6RWlEPTB;MUCuPFI4PCEQvF2= M1\LWXNCVkeHUh?=
NOS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\iXIdKSzVyPUGwMlg1PzJizszN NHPZWXBUSU6JRWK=
A3-KAW M2TI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPVS417UUN3ME2xNU44OTd6IN88US=> MofOV2FPT0WU
SK-LU-1 M4D6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XVTGlEPTB;MUKuNlY2PSEQvF2= NVXwR|h2W0GQR1XS
TYK-nu NEC0VlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF{LkO5N|Ih|ryP NX20[GduW0GQR1XS
NMC-G1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvNemlKSzVyPUGyMlYxPjJizszN NEHve2xUSU6JRWK=
D-566MG M13PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXDSYJJUUN3ME2xN{46PTd4IN88US=> MVPTRW5ITVJ?
KYSE-140 M3znemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKyXIFKSzVyPUG0MlA4PTNizszN NWDT[YRwW0GQR1XS
U251 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD1zND64OFkzKM7:TR?= NX3WU5lNW0GQR1XS
D-542MG NGq1cmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInGbmdKSzVyPUG0MlkzOjJizszN NHvsNWNUSU6JRWK=
LAMA-84 NXvlZ2NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF2Lkm5N|Ih|ryP NWiyPJp6W0GQR1XS
NCI-H720 NWnWbll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\lTWM2OD1zNT6yOlg1KM7:TR?= NXqwTZc1W0GQR1XS
DEL MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF3LkSyPVMh|ryP MYfTRW5ITVJ?
SBC-1 M3jWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[0TWM2OD1zNT60N|A2KM7:TR?= MVHTRW5ITVJ?
MZ2-MEL NYPz[nE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\YW3pKSzVyPUG2MlA3PDZizszN M3PXR3NCVkeHUh?=
CAL-12T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPh[5NKSzVyPUG2MlQ5PjJizszN MX7TRW5ITVJ?
KE-37 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF4LkixNFch|ryP NVPOeJhiW0GQR1XS
NCI-H2228 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF5LkOwO|Eh|ryP MoTaV2FPT0WU
SK-MEL-2 NFm2c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF5LkS5OlUh|ryP NU\BSHZyW0GQR1XS
HN Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;IcmlEPTB;MUeuO|I1QCEQvF2= M{\KSnNCVkeHUh?=
NCI-H1648 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7ITWM2OD1zNz64NVgh|ryP NEnUOpVUSU6JRWK=
IA-LM NF:4TGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF6LkOxO|Ih|ryP M3zsSXNCVkeHUh?=
EW-13 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[0TWM2OD1zOD61O|A5KM7:TR?= NF\qclFUSU6JRWK=
KNS-81-FD M3;DZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDnZY16UUN3ME2xPU42QDV6IN88US=> MmXvV2FPT0WU
23132-87 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vOSGlEPTB;MUmuO|Y1OiEQvF2= M2DmTXNCVkeHUh?=
NUGC-3 NGLVUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHWWphKSzVyPUG5Mlk5QDdizszN NYHYfopIW0GQR1XS
5637 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJyLkC0O|gh|ryP M1L6[XNCVkeHUh?=
NCI-H1755 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\rTWM2OD1{MD60O|Y1KM7:TR?= MlzzV2FPT0WU
RXF393 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJyLk[3OVYh|ryP NVSxe3lGW0GQR1XS
TE-12 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rUNWlEPTB;MkCuO|IxOSEQvF2= MU\TRW5ITVJ?
MOLT-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XGcmlEPTB;MkGuNVkyPSEQvF2= MmTSV2FPT0WU
IGR-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\PXWlEPTB;MkGuN|c6PiEQvF2= M1HUfHNCVkeHUh?=
HOP-92 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHwdFlKSzVyPUKxMlQ6QDdizszN MoL2V2FPT0WU
LU-65 M4HpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV35N2M5UUN3ME2yNU45PjJ2IN88US=> M4TGTXNCVkeHUh?=
LoVo NX\vOZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjaOJFtUUN3ME2yNk4zPDRizszN MmrLV2FPT0WU
A704 M4TNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T0UmlEPTB;MkKuOVE2PSEQvF2= NWHVT2xWW0GQR1XS
HT-1376 NHTFVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fCbmlEPTB;MkKuOlA2QSEQvF2= NH3DNG9USU6JRWK=
IST-MEL1 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n5V2lEPTB;MkKuOlc2OSEQvF2= MnXpV2FPT0WU
Ramos-2G6-4C10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHXTWM2OD1{Mj63N|Y3KM7:TR?= MVjTRW5ITVJ?
T47D Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ{Lke5O|kh|ryP MX;TRW5ITVJ?
HT-1197 NF7Z[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ|LkC4NVch|ryP M{jERXNCVkeHUh?=
LB2518-MEL Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnTepdKSzVyPUKzMlY1OTJizszN Ml\yV2FPT0WU
J-RT3-T3-5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnTXmk4UUN3ME2yOE44PTl3IN88US=> NVLPZ4h2W0GQR1XS
IST-SL1 M{HMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnmTWM2OD1{NT6yO|UyKM7:TR?= M3Tqd3NCVkeHUh?=
NCI-H82 M{DkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrvTWM2OD1{NT65N|gh|ryP MVnTRW5ITVJ?
SNU-449 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\BZYFKSzVyPUK3MlIxOThizszN NW[4dJl5W0GQR1XS
COR-L23 M{nOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjYTWM2OD1{Nz6yPFE{KM7:TR?= MXXTRW5ITVJ?
LOXIMVI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DK[mlEPTB;MkeuN|Y5KM7:TR?= M3LZbHNCVkeHUh?=
GR-ST M2ntfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnIXpBEUUN3ME2yO{43PzB4IN88US=> MnHUV2FPT0WU
ALL-PO NU[yT5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\nT2lEPTB;MkiuNVYxPCEQvF2= MlHwV2FPT0WU
ML-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnixTWM2OD1{OD6yPFE1KM7:TR?= MlfWV2FPT0WU
LB996-RCC NVHjfpJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnjRlBKSzVyPUK5MlU3QDJizszN M3PRXnNCVkeHUh?=
LCLC-97TM1 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T2U2lEPTB;M{KuNVk3PCEQvF2= M1\WXHNCVkeHUh?=
NCI-H1304 NVH3bVZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr6OXl7UUN3ME2zNk4{OzBzIN88US=> MmTSV2FPT0WU
KP-N-YS NE\Me25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5VoJRUUN3ME2zNk42QTd|IN88US=> NEC4emhUSU6JRWK=
EM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN|Lk[1NFQh|ryP MmS2V2FPT0WU
ChaGo-K-1 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN|LkeyN|Yh|ryP MWnTRW5ITVJ?
ACHN Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HjOmlEPTB;M{OuPFM5PSEQvF2= M4DxdXNCVkeHUh?=
MN-60 NEXoSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvFTWM2OD1|Mz64OVQ1KM7:TR?= NYrhe5VLW0GQR1XS
EW-18 M3Lkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ZbIF3UUN3ME2zN{45QTdzIN88US=> NFXaNWJUSU6JRWK=
KGN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DReGlEPTB;M{WuO|I6OiEQvF2= MlzQV2FPT0WU
U031 NGP1eZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN3LkixN|Ih|ryP NWLZZ4F6W0GQR1XS
L-363 M{njOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXZVFNJUUN3ME2zO{43PDV3IN88US=> MUDTRW5ITVJ?
NCI-H1155 M1iyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ORXhKSzVyPUO4MlAxOTVizszN NEPQbXhUSU6JRWK=
NCI-H1793 NV7LV3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rCZ2lEPTB;M{iuNVAzPiEQvF2= M4nOU3NCVkeHUh?=
P30-OHK NEfybWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN6LkGzN|Ih|ryP NVHaR49oW0GQR1XS
AN3-CA NH\PW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELyeohKSzVyPUO4MlE3OTVizszN MVfTRW5ITVJ?
UACC-257 M2XTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTH[XRlUUN3ME2zPE44QSEQvF2= MmnzV2FPT0WU
MCF7 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHx[YFKSzVyPUO5Mlg3OjlizszN MnnkV2FPT0WU
KP-N-YN M1nrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvjSZBKSzVyPUSwMlQzQDVizszN M120T3NCVkeHUh?=
T98G MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n0cGlEPTB;NECuOFk2PyEQvF2= NWO2WndOW0GQR1XS
HGC-27 NH3aWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:wNII6UUN3ME20N{4zPzRizszN MnjIV2FPT0WU
NCI-H1092 NGi2SY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzOItKSzVyPUSzMlI5QTVizszN M1f5Z3NCVkeHUh?=
KARPAS-299 M{e4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpVmlEPTB;NEOuN|A4OSEQvF2= NGLyZ4dUSU6JRWK=
LB1047-RCC NG\MW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe0TFJKSzVyPUS0Mlk6PTlizszN M2LXN3NCVkeHUh?=
786-0 NH;KN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ix[GlEPTB;NEWuOlUh|ryP MULTRW5ITVJ?
HCC2157 M336eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR4LkCzOVkh|ryP MlLPV2FPT0WU
EFM-19 NUHNXVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR4Lke1N|Mh|ryP M{jHTXNCVkeHUh?=
EW-16 M1;qTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DBPWlEPTB;NE[uO|gxPiEQvF2= M3The3NCVkeHUh?=
UM-UC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPYTWM2OD12Nj64NFU6KM7:TR?= NELWfolUSU6JRWK=
HT-29 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR5Lki3PVIh|ryP NX\hZ4NYW0GQR1XS
LN-405 M1fMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvbmlEPTB;NEiuNFgzPyEQvF2= M{XLZ3NCVkeHUh?=
D-502MG NHf4eIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi1fpZ4UUN3ME20PE46Pjd4IN88US=> MWTTRW5ITVJ?
GMS-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljGTWM2OD12OT6yPVc1KM7:TR?= NXnIRmY{W0GQR1XS
MEL-JUSO M1Lyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLsTWM2OD12OT6zOFch|ryP NYHlfpRtW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]


Kinase Assay:[1]
+ Expand

In vitro Raf kinase activities:

The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:[1]
+ Expand
  • Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 mM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
  • Formulation: Suspended in vehicle (5% DMSO, 1% methylcellulose)
  • Dosages: 5, 20, or 100 mg/kg
  • Administration: Oral gavage once or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.83


CAS No. 918505-84-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you recommend to make working solution for intraperitoneal injection into mice?

  • Answer:

    PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy PLX-4720 | PLX-4720 supplier | purchase PLX-4720 | PLX-4720 cost | PLX-4720 manufacturer | order PLX-4720 | PLX-4720 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID